Indian company Intas Biopharmaceuticals has acquired US-based biotechnology enterprise Biologics Process Development Inc (BPD Inc) based in Poway, California. With the acquisition process underway, both Intas and BPD Inc are actively pursuing plans to work closely toward fulfilment of common business objectives in the area of biologics contract research and manufacturing services (CRAMS). No financial details of the transaction have been revealed.
Intas says that this development will facilitate and assist its foray into the US marketplace especially to expand its CRAMS business. With mutual understanding and agreement between the two companies, Scott Brown, founder, president and chief scientific officer of the US concern will continue in both executive capacities.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze